Paolo Tombesi - Jul 26, 2021 Form 4 Insider Report for Turning Point Therapeutics, Inc. (TPTX)

Role
EVP & Chief Financial Officer
Signature
/s/ Annette North, Attorney-in-Fact
Stock symbol
TPTX
Transactions as of
Jul 26, 2021
Transactions value $
$0
Form type
4
Date filed
7/27/2021, 06:22 PM
Next filing
Feb 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TPTX Common Stock Award $0 +13.6K $0.00 13.6K Jul 26, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TPTX Stock Option (right to buy) Award $0 +61.2K $0.00 61.2K Jul 26, 2021 Common Stock 61.2K $62.63 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan.
F2 25% of the shares vest on July 26, 2022 and 1/48th of the shares vest monthly thereafter over the next three years.